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Abstract
Identifying microbial pathogens with zoonotic potential in wild-living primates can be important to human health, as
evidenced by human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2) and Ebola virus. Simian foamy viruses
(SFVs) are ancient retroviruses that infect Old and New World monkeys and apes. Although not known to cause disease,
these viruses are of public health interest because they have the potential to infect humans and thus provide a more
general indication of zoonotic exposure risks. Surprisingly, no information exists concerning the prevalence, geographic
distribution, and genetic diversity of SFVs in wild-living monkeys and apes. Here, we report the first comprehensive
survey of SFVcpz infection in free-ranging chimpanzees (Pan troglodytes) using newly developed, fecal-based assays.
Chimpanzee fecal samples (n=724) were collected at 25 field sites throughout equatorial Africa and tested for SFVcpz-
specific antibodies (n=706) or viral nucleic acids (n=392). SFVcpz infection was documented at all field sites, with
prevalence rates ranging from 44% to 100%. In two habituated communities, adult chimpanzees had significantly higher
SFVcpz infection rates than infants and juveniles, indicating predominantly horizontal rather than vertical transmission
routes. Some chimpanzees were co-infected with simian immunodeficiency virus (SIVcpz); however, there was no
evidence that SFVcpz and SIVcpz were epidemiologically linked. SFVcpz nucleic acids were recovered from 177 fecal
samples, all of which contained SFVcpz RNA and not DNA. Phylogenetic analysis of partial gag (616 bp), pol-RT (717 bp),
and pol-IN (425 bp) sequences identified a diverse group of viruses, which could be subdivided into four distinct SFVcpz
lineages according to their chimpanzee subspecies of origin. Within these lineages, there was evidence of frequent
superinfection and viral recombination. One chimpanzee was infected by a foamy virus from a Cercopithecus monkey
species, indicating cross-species transmission of SFVs in the wild. These data indicate that SFVcpz (i) is widely distributed
among all chimpanzee subspecies; (ii) is shed in fecal samples as viral RNA; (iii) is transmitted predominantly by
horizontal routes; (iv) is prone to superinfection and recombination; (v) has co-evolved with its natural host; and (vi)
represents a sensitive marker of population structure that may be useful for chimpanzee taxonomy and conservation
strategies.
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Foamy viruses (also termed spumaviruses) are complex
retroviruses that naturally infect numerous mammal species,
including primates, felines, bovines and equines, but not humans
[1–4]. Simian foamy viruses (SFVs) have been identified in a wide
variety of primates, including prosimians, New World and Old
World monkeys as well as apes, and each species has been shown
to harbor a unique (species-specific) strain of SFV [5–13].
Moreover, closely related SFVs have been isolated from closely
related primate species: a comparison of phylogenies derived from
SFV integrase and primate mitochondrial DNA sequences
revealed highly congruent relationships, indicating virus-host co-
evolution for at least 30–40 million years [13]. This ancient
relationship may be responsible for the non-pathogenic phenotype
of SFV: Although highly cytopathic in tissue culture, the various
SFVs do not seem to cause any recognizable disease in their
natural hosts [2,3,14]. SFVs are highly prevalent in captive
primate populations, with infection rates ranging from 70% to
100% in adult animals [2,3,5,15–19]. Transmission is believed to
occur through saliva because large quantities of viral RNA,
indicative of SFV gene expression and replication, are present in
cells of the oral mucosa [3,20–22]. However, little is known about
the prevalence and transmission patterns of SFV in wild-living
primate populations.
Although there is no human counterpart of SFV, humans are
susceptible to cross-species infection by foamy viruses from various
primate species. Indeed, the first ‘‘human foamy virus’’ [23]
isolated from a Kenyan patient with nasopharyngeal carcinoma
more than three decades ago was subsequently identified to be of
chimpanzee origin [7,8]. Since then, SFV strains from African
green monkeys, baboons, macaques and chimpanzees have been
identified in zookeepers and animal caretakers who acquired these
infections through occupational exposure to primates in captivity
[19,24–27]. More recently, about 1% of Cameroonian villagers
who were exposed to primates through hunting, butchering and
the keeping of pet monkeys were found to be SFV antibody
positive, and genetic analysis of three such cases documented
infection with SFV strains from DeBrazza’s monkeys, mandrills
and gorillas [10]. Finally, a large proportion of individuals (36%)
who were severely bitten and injured while hunting wild
chimpanzees and gorillas had detectable SFVcpz or SFVgor
sequences in their blood [28]. Thus, humans are susceptible to a
wide variety of SFVs and seem to acquire these viruses more
readily than other retroviruses of primate origin, such as simian
immunodeficiency viruses (SIVs) or simian T-lymphotropic viruses
(STLVs). Interestingly, these infections appear to be non-
pathogenic and thus far exhibit no evidence of onward
transmission by human-to-human contact; however, additional
studies will need to be conducted to fully characterize the natural
history of SFV infections in humans [10,24,28–30].
Among wild primates, chimpanzees (Pan troglodytes) are of
particular public health interest since they harbor SIVcpz, the
precursor of the human immunodeficiency virus type 1 (HIV-1)
[31–34]. There are four proposed chimpanzee subspecies which
have been defined on the basis of geography and differences in
mitochondrial DNA (mtDNA) sequences [35,36]. These include P.
t. verus in west Africa, P. t. vellerosus in Nigeria and northern
Cameroon, P. t. troglodytes in southern Cameroon, Gabon,
Equatorial Guinea and the Republic of Congo, and P. t.
schweinfurthii in the Democratic Republic of Congo and countries
to the east (Figure 1). Two of these, P. t. troglodytes and P. t.
schweinfurthii, are naturally infected with SIVcpz, but only P. t.
troglodytes apes have served as a reservoir of human infection [31–
34]. It is now well established that SIVcpzPtt has been transmitted
to humans on at least three occasions, generating HIV-1 groups
M, N and O. Moreover, two of these cross-species infections
(groups M and N) have been traced to distinct P. t. troglodytes
communities in southeastern and southcentral Cameroon, respec-
tively [33]. The reason for the emergence of SIVcpzPtt strains, but
not SIVcpzPts strains, in humans is unknown, but could reflect
regional differences in the types and frequencies of human/
chimpanzee encounters. Thus, examining humans for SFVcpz
infection might be informative as to the location(s) where human/
chimpanzee contacts are most common; however, no information
exists regarding the prevalence, geographic distribution and
genetic diversity of SFVcpz in chimpanzees in the wild.
In this study, we sought to develop an experimental strategy that
would allow us to identify and molecularly characterize SFVcpz
infection in wild-living chimpanzees by entirely non-invasive
means. The rationale for this approach was two-fold. First, we
wished to explore whether large scale screening of endangered
primates for infectious agents other than primate lentiviruses was
feasible. Second, we wished to examine whether SFVcpz could
serve as a test case in efforts to develop suitable early warning
systems for pathogens that might infect humans exposed to wild
animals. To this end, we tested whether fecal based methods
previously developed for SIVcpz could be adapted to the non-
invasive detection and molecular characterization of SFVcpz. Our
results show that this was indeed possible. Using these newly
developed methods, we determined the prevalence of SFVcpz
infection in wild chimpanzee communities throughout equatorial
Africa, molecularly characterized 120 new SFVcpz strains,
examined the subspecies association and phylogeography of
SFVcpz, documented numerous instances of SFVcpz co-infection
and recombination, investigated the routes of SFVcpz transmis-
sion in the wild, and examined the frequency of SFV cross-species
transmissions from prey species. Our results reveal important new
insights into the molecular ecology and natural history of SFVcpz
infection that could not have been gained from studies of captive
Author Summary
Cross-species transmissions of infectious agents from
primates to humans have led to major disease outbreaks,
with AIDS representing a particularly serious example. It
has recently been shown that humans who hunt primates
frequently acquire simian foamy virus (SFV) infections.
Thus, these viruses have been proposed as an ‘‘early
warning system’’ of human exposure to wild primates. In
this study, we have tested this concept by developing non-
invasive methods to determine the extent to which wild
chimpanzees are infected with SFV. We analyzed more
than 700 fecal samples from 25 chimpanzee communities
across sub-Saharan Africa and obtained viral sequences
from a large number of these. SFV was widespread among
all chimpanzee subspecies, with infection rates ranging
from 44% to 100%. The new viruses formed subspecies-
specific lineages consistent with virus/host co-evolution.
We also found mosaic sequences due to recombination,
indicating that chimpanzees can be infected with multiple
viral strains. One chimpanzee harbored an SFV from a
monkey species, indicating cross-species transmission in
the wild. These data indicate that chimpanzees represent a
substantial natural reservoir of SFV. Thus, monitoring
humans for these viruses should identify locations where
human/chimpanzee encounters are most frequent, and
where additional transmissions of chimpanzee pathogens
should be anticipated.
SFVcpz in Wild Chimpanzees
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can be studied by non-invasive molecular approaches to elucidate
the circumstances and mechanisms of pathogen transmission.
Results
Fecal-based methods for SFVcpz antibody and nucleic
detection
SFV infection of primates and humans is generally diagnosed by
documenting virus specific anti-Gag antibodies in serum or plasma
using ELISA and/or Western blot approaches [8,10,18,19]. The
infecting SFV strain is then molecularly characterized by
amplifying viral DNA from peripheral blood mononuclear cell
(PBMC) or other tissue DNA [8,10,11,13,16–18,24,26,28]. Since
collecting blood from wild chimpanzees is not feasible, we sought
to develop methods of SFVcpz detection that are entirely fecal-
based. To accomplish this, we examined whether existing methods
of SIVcpz fecal antibody and nucleic acid detection [33,37,38]
could be adapted to the non-invasive identification and molecular
characterization of SFVcpz.
Western blot strips were prepared from sucrose purified SFVcpz
virions and used to test 40 fecal extracts from 23 SFVcpz infected
chimpanzees from the Yerkes Primate Research Center (Table 1).
Reactivity with the two SFVcpz Gag proteins p74 and p71 was
scored positive, following interpretive guidelines established for
serum antibody positivity [8,10,18]. The absence of viral bands
was scored negative, and samples that did not meet either criterion
were classified as indeterminant. Using this approach, SFVcpz
specific IgG antibodies were detected in 29 of 40 fecal extracts
from infected chimpanzees (Table 1). All samples reacted with the
Gag doublet and a subset also recognized the accessory Bet (p60)
protein (Figure 2A). In contrast, none of 21 fecal extracts from
uninfected human volunteers exhibited false-positive or indeter-
minant Western blot reactivities (Figure 2A; Table 1).
We also investigated whether SFVcpz nucleic acids could be
detected in fecal samples using primers designed to amplify a
conserved 425 bp fragment (pol-IN) in the viral pol gene (Figure 3)
[11–13,18]. In vitro studies have shown that foamy viruses, in
contrast to other retroviruses, reverse transcribe their RNA
genome before they assemble into virus particles and bud from
infected cells [39,40]. Thus, infectious foamy virus particles have
been reported to contain mostly viral DNA, while productively
infected cells contain mostly viral RNA [1,40,41]. Using nested
PCR to analyze fecal samples from the 21 infected chimpanzees,
we found SFVcpz DNA in only 2 of 40 samples (Table 1).
However, RT-PCR of fecal RNA from these same specimens
yielded amplification products for 30 samples. Sequence analysis
confirmed the authenticity of the amplification products and
identified 11 distinct SFVcpz strains (Table 1). Omission of the
cDNA synthesis step during the RT-PCR procedure failed to yield
detectable amplification products. These results thus indicate that
SFVcpz is present in chimpanzee fecal samples mostly as viral
RNA, the source of which (cell associated, cell free, or both)
remains to be determined.
The sensitivities of SFVcpz antibody and viral nucleic acid
detection in fecal samples from captive chimpanzees were
determined to be 73% and 75%, respectively (Table 2). Assay
specificities were 100% (Table 1). Interestingly, not all fecal vRNA
positive chimpanzees were also fecal Western blot positive (and
vice versa). Two SFVcpz infected apes (CPZ6, CPZ23), each of
whom had detectable RNA in at least two independent stool
samples, were repeatedly fecal antibody negative (Table 1). Since
both individuals had high titer antibodies in their blood, this was
not due to a recently acquired SFVcpz infection. Two other apes
(CPZ7, CPZ20) were fecal antibody positive, but virion RNA
negative (Table 1). Thus, antibody or virion RNA screening alone
would have missed SFVcpz infection in these individuals.
Nonetheless, Western blot together with RT-PCR correctly
Figure 1. Location of wild chimpanzee study sites. Field sites are shown in relation to the ranges of the four proposed chimpanzee subspecies.
White circles indicate forest areas where fecal samples were collected for prevalence studies (Table 3). These were located in Cote d’Ivoire (TA),
Cameroon (MF, WE, MP, MT, DG, DP, BQ, CP, EK, BB, MB, LB), the Central African Republic (ME), Gabon (LP), Republic of Congo (GT), Democratic
Republic of Congo (BD, WL, WK), Uganda (KB), Rwanda (NY), and Tanzania (GM-MT, GM-KK, GM-KL, MH). Black circles indicate forest sites where eight
ancillary samples (BA432, BF1167, EP479, EP486, KS310, UB446, WA466, WA543) were collected. International borders and major rivers are shown.
doi:10.1371/journal.ppat.1000097.g001
SFVcpz in Wild Chimpanzees
PLoS Pathogens | www.plospathogens.org 3 July 2008 | Volume 4 | Issue 7 | e1000097diagnosed SFVcpz infection in 21 of 23 captive chimpanzees,
suggesting that the newly developed assays were of sufficient
sensitivity and specificity for field surveys, especially when used in
combination.
Geographic distribution, subspecies association and
prevalence of SFVcpz in wild-living chimpanzees
To determine to what extent chimpanzees are infected with
SFVcpz in the wild, we tested 724 fecal samples from 25 different
field sites across equatorial Africa for virus specific antibodies and/
or viral RNA (Table 3). Samples were selected from existing
specimen banks based on their geographic representation,
available host genetic information (mtDNA, microsatellite and
sex markers), and remaining quantities of material. Figure 1
depicts the geographic location of the sites with respect to the
ranges of the four proposed chimpanzee subspecies. Except for P.
t. verus, all other subspecies were sampled at multiple sites.
Specimens from the Taı ¨ Forest (TA) as well as from Gombe (GM-
MT, GM-KK) and Mahale Mountains (MH) National Parks were
collected from individually known (habituated) chimpanzees under
direct observation. Samples from the Goualougo Triangle (GT),
several field sites in Cameroon (DP, EK, BB, MB, LB), and the
Kalande community (GM-KL) in Gombe National Park were
obtained from non-habituated chimpanzees, but were subsequent-
ly genotyped using mtDNA, microsatellite and sex markers and
thus also represent known numbers of individuals [33] (B. Keele
and B. H. Hahn, unpublished). Samples from the remaining field
sites in Cameroon (MF, MP, WE, MT, BQ, DG, CP), Gabon (LP),
the Central African Republic (ME), the Democratic Republic of
Congo (BD, WL, WK), Rwanda (NY) and Uganda (KB) were
derived from an unknown number of chimpanzees. All samples
were previously screened for SIVcpz antibodies and/or vRNA
[33,37,42] (F. van Heuverswyn and M. Peeters, unpublished) and
their integrity was confirmed by mtDNA analysis (Table S1).
Of 724 fecal samples included in the analysis (Table 3), 706
were tested by Western blot analysis and 211 were found to be
SFVcpz antibody positive (18 samples were of insufficient quantity
for immunoblot analysis but were used for RT-PCR amplifica-
tion). All of these reacted with the Gag p74/p71 doublet and a
small number also recognized the p60 Bet protein (Figure 2B).
Table 1. Validation of Fecal-Based Antibody and Nucleic Acid Detection Assays Using Samples from SFVcpz Infected Captive
Chimpanzees and Uninfected Human Volunteers.
Captive
chimpanzees
a
Antibody
positive samples/
number tested
vRNA positive
samples/ number
tested
vDNA positive
samples/ number
tested
SFVcpz
strains
b
Human
Volunteers
Antibody
positive
samples/
number tested
vRNA positive
samples/
number
tested
vDNA positive
samples/
number tested
CPZ 1 2/2 2/2 2/2 YK3 HUM 1 0/1 0/1 0/1
CPZ 2 1/1 1/1 0/1 YK3 HUM 2 0/1 0/1 0/1
CPZ 3 2/2 2/2 0/2 YK3 HUM 3 0/1 0/1 0/1
CPZ 4 2/2 1/2 0/2 YK5 HUM 4 0/1 0/1 nd
c
CPZ 5 1/1 1/1 0/1 YK2 HUM 5 0/1 0/1 nd
CPZ 6 0/5 3/5 0/5 YK3 HUM 6 0/1 0/1 nd
CPZ 7 1/1 0/1 0/1 n/a
b HUM 7 0/1 0/1 nd
CPZ 8 3/3 1/3 0/3 YK18 HUM 8 0/1 0/1 nd
CPZ 9 1/1 1/1 0/1 YK5 HUM 9 0/1 0/1 nd
CPZ 10 1/1 1/1 0/1 YK15 HUM 10 0/1 0/1 nd
CPZ 11 1/1 1/1 0/1 YK18 HUM 11 0/1 0/1 nd
CPZ 12 2/2 2/2 0/2 YK26 HUM 12 0/1 0/1 nd
CPZ 13 4/4 4/4 0/4 YK22 HUM 13 0/1 0/1 nd
CPZ 14 1/1 1/1 0/1 YK23 HUM 14 0/1 0/1 nd
CPZ 15 1/1 1/1 0/1 YK29 HUM 15 0/1 0/1 nd
CPZ 16 2/2 2/2 0/2 YK30 HUM 16 0/1 0/1 nd
CPZ 17 0/1 1/1 0/1 YK32 HUM 17 0/1 0/1 nd
CPZ 18 2/2 2/2 0/2 YK15 HUM 18 0/1 0/1 nd
CPZ 19 1/1 1/1 0/1 YK15 HUM 19 0/1 0/1 nd
CPZ 20 1/2 0/2 0/2 n/a HUM 20 0/1 0/1 nd
CPZ 21 0/1 0/1 0/1 n/a HUM 21 0/1 0/1 nd
CPZ 22 0/1 0/1 0/1 n/a
CPZ 23 0/2 2/2 0/2 YK3
n=23 29/40 30/40 2/40 n=21 0/21 0/21 0/3
aAll chimpanzees were housed at the Yerkes Primate Research Center; SFVcpz infection was confirmed by demonstrating virus specific (anti-Gag) antibodies in their
blood.
bThe phylogenetic relationships of SFVcpz strains YK2-YK32 strains are shown in Figures 6–8.
bn/a, not available.
cnd, not done.
doi:10.1371/journal.ppat.1000097.t001
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Bet protein and were thus classified as indeterminant (not shown).
The remaining 493 fecal extracts exhibited no detectable bands
and were thus classified as antibody (SFVcpz IgG) negative. A
subset of samples (n=392) was also examined for SFVcpz nucleic
acids (Table 3). RT-PCR of fecal RNA yielded pol-IN (425 bp)
amplification products for 175 samples, all of which were shown to
contain SFVcpz sequences (two samples were RT-PCR positive
using LTR and pol-RT primers, respectively). In contrast,
amplification of fecal DNA from these same samples failed to
yield viral sequences (not shown), providing further evidence for
the presence of SFVcpz RNA, and not DNA, in fecal material. A
breakdown of antibody and RNA positive samples for each field
site is shown in Table 3. The results revealed SFVcpz infected
chimpanzees at all field sites.
We next sought to determine the prevalence of SFVcpz
infection at each of the 25 field sites. To accomplish this, we
examined whether fecal antibody and vRNA detection tests
yielded similar data for captive as well as wild communities.
Inspection of Table 3 indicated that this was not the case. For
example, at the TA field site all of 16 fecal samples were SFVcpz
antibody positive (100%), but only 7 contained vRNA (44%). In
contrast, at the ME field site none of 21 fecal samples contained
antibodies (0%), while 16 were vRNA positive (76%). Importantly,
the latter was not due to a lack of antibody cross-reactivity since
other P. t. troglodytes samples (e.g., 11 of 20 GT samples) were
Western blot positive using the same antigens (Table 3, Figure 2B).
To examine this further, we re-calculated test sensitivities using
only samples from SFVcpz infected wild chimpanzees (Table 2).
This yielded surprising results: not only did test results vary
extensively between different field sites, the sensitivities of antibody
and vRNA detection were also inversely correlated (Figure 4). To
account for this in prevalence estimations, we decided to calculate
a ‘‘field sensitivity’’ for each test by averaging values across all
collection sites. The rationale for this was that the strong negative
correlation between the two assay sensitivities would predict that if
the sensitivity of one test was underestimated, the sensitivity of the
other test would be overestimated to a roughly similar degree.
Thus, if samples were subject to an equal number of both tests,
these effects would tend to even out. While many samples were not
subject to equal numbers of the two tests, this nonetheless seemed
to represent the most reasonable approach. For both Western blot
and RT-PCR assays, the average sensitivities across all sites were
around 56%. Therefore we pooled results from all tests to obtain a
general sensitivity value (56.3%) that was then used to calculate the
prevalence rates.
Table 3 summarizes the prevalence of SFVcpz infection at 25
different field sites. For 11 sites, these values were calculated based
on the proportion of infected individuals. For the remaining sites,
prevalence rates were estimated based on the proportion of
antibody and/or vRNA positive fecal samples, but correcting for
repeat sampling and sample degradation (see Methods). The
results revealed uniformly high infection rates for all sites, similar
to previously reported values for captive primate populations [15–
19]. The highest prevalences (.90%) were found at a P. t. verus
field site in Cote d’Ivoire (TA); two P. t. vellerosus field sites in
central Cameroon (MF, MP); four P. t. troglodytes field sites in
Cameroon (DG, CP), Gabon (LP) and the Central African
Republic (ME); and three P. t. schweinfurthii field sites in the DRC
(BD), Uganda (KB) and Tanzania (GM-MT). The lowest infection
rates (,60%) were identified at three P. t. troglodytes field sites in
southern Cameroon (BQ, MB, LB). Given that the confidence
intervals for the prevalence estimates across the various sites
showed extensive overlap (Table 3), these differences are unlikely
to be significant. These data thus indicate that SFVcpz is widely
distributed and infects chimpanzees at very high prevalence rates
throughout their natural habitat.
Documentation of SFVcpz/SIVcpz co-infections
The fact that all 724 fecal samples had independently been
tested for SIVcpz antibodies and/or viral nucleic acids provided
an opportunity to compare the two viruses with respect to their
relative infection frequencies and geographic distribution. As
reported previously, natural SIVcpz infection has been identified
only in two of the four chimpanzee subspecies (P. t. troglodytes and
P. t. schweinfurthii), and then only in a fraction of sampled
communities [33,37,42]. Thus, SIVcpz is clearly much less
common and widespread among wild chimpanzees than is
SFVcpz. Nonetheless, the current survey included field sites where
Figure 2. Detection of SFVcpz antibodies in chimpanzee fecal
samples. Enhanced chemiluminescent (ECL) Western blot analysis of
fecal extracts from (A) human volunteers and captive chimpanzees, and
(B) SFVcpz infected wild chimpanzees representing four different
chimpanzee subspecies. Strips were prepared using an infectious
molecular clone (pMod-1) of SFVcpzPts (see Methods). Samples are
numbered, with letters indicating the species (panel A) or collection site
(panel B) of origin. Molecular weights of SFVcpz specific Gag and Bet
proteins are shown. The banding pattern of plasma from an SFVcpz
infected chimpanzee (used at a 1:100,000 dilution) and an uninfected
human are shown as positive (Pos) and negative (Neg) controls,
respectively.
doi:10.1371/journal.ppat.1000097.g002
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whether the two infections were epidemiologically linked, we
selected seven sites with known numbers of SFVcpz and/or
SIVcpz infected chimpanzees. Four of these were located in
Cameroon (MB, LB, EK, DP), while the other three were located
in Gombe National Park in Tanzania (GM-KK, GM-KL, GM-
MT). Table 4 summarizes the results: Of a total of 130
chimpanzees tested, 55 were infected only with SFVcpz, 7 were
infected only with SIVcpz, and 15 harbored both viruses. Thus,
SFVcpz/SIVcpz co-infections are not uncommon at locations
where both viruses are endemic; however, examination of the
relative frequencies of single and dual infections at individual sites,
or sites in combination, revealed no association between SFVcpz
and SIVcpz (Fisher exact test; P.0.2). Thus, there was no
evidence that infection with one of these viruses increased or
decreased the likelihood of infection by the other.
Patterns of SFVcpz transmission in the wild
To determine under what circumstances chimpanzees acquire
SFVcpz in the wild, we screened members of two habituated
communities for evidence of infection. The Kasekela and
Mitumba communities are located in Gombe National Park and
have been under human observation since the 1960s and 1980s,
respectively [43]. Chimpanzees from both communities are
followed daily (with particular individuals selected for all-day
observation) and their reproductive states and social interactions
are recorded. Thus, for many Mitumba and Kasekela apes,
especially the more recent offspring, the date of birth is known.
Table 2. Sensitivities of Antibody and Viral RNA Detection in Fecal Samples From Captive and Wild Chimpanzees.
Sites
c Individuals
d SFVcpz Western blot
a SFVcpz RT-PCR
b
Positive samples/
number tested Sensitivity(95% CI)
e
Positive samples/
number tested Sensitivity (95% CI)
e
Captive Apes
YK 23 29/40 0.73 (0.59–0.84) 30/40 0.75 (0.61–0.86)
Wild-living Apes
TA 16 16/16 1.00 (0.83–1.00) 7/16 0.44 (0.23–0.67)
DP 24 20/62 0.32 (0.23–0.43) 19/28 0.68 (0.51–0.82)
EK 8 2/10 0.20 (0.04–0.51) 7/9 0.78 (0.45–0.96)
BB 10 1/13 0.08 (0.00–0.32) 10/10 1.00 (0.74–1.00)
MB 8 8/13 0.62 (0.35–0.83) 6/8 0.75 (0.40–0.95)
LB 4 1/8 0.13 (0.01–0.47) 4/5 0.80 (0.34–0.99)
GT 9 11/15 0.73 (0.49–0.90) 5/15 0.33 (0.14–0.58)
GM 26 43/51 0.84 (0.73–0.92) 16/32 0.50 (0.34–0.66)
MH 9 11/12 0.92 (0.66–1.00) 1/11 0.09 (0.00–0.36)
aWestern blot strips were prepared using an infectious molecular clone (pMod-1) of SFVcpzPts (see Methods).
bRT-PCR was performed using SFVcpz specific pol-IN primers.
cSensitivities of SFVcpz antibody and viral RNA detection were determined for captive (YK) as well as wild-living chimpanzees at different field sites (TA, DP, EK, BB, MB,
LB, GT, GM, MH).
dSFVcpz infection in captive chimpanzees was confirmed by demonstrating virus specific antibodies in their blood; SFVcpz infection of wild-living chimpanzees was
determined by demonstrating virus specific antibodies or viral RNA in at least one fecal sample.
eThe sensitivities of fecal antibody and viral RNA detection were calculated for each site based on the total number of samples collected from infected chimpanzees at
that site (with 95% confidence intervals [CI]); the specificity of fecal antibody detection was determined by testing fecal samples from uninfected human volunteers
(Table 1) and determined to be 1.00 (0.87–1.00); the specificity of virion RNA detection was set to 1.00 since all amplification products were sequence confirmed.
doi:10.1371/journal.ppat.1000097.t002
Figure 3. Location of RT-PCR derived amplicons in the SFVcpz genome. Amplification products are shown in relation to the corresponding
regions in the SFVcpz genome, with the length of the amplified fragments indicated. The genomic organization of SFVcpz is shown on the top
(structural and accessory genes are drawn to scale) [79].
doi:10.1371/journal.ppat.1000097.g003
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SFVcpz infection among individuals representing different age
groups. Testing the most recent fecal sample available, we found
no evidence of SFVcpz infection in four infants age 2 years or
younger. In addition, only three of ten chimpanzees ages 2.1 to 9
years were found to be SFVcpz antibody and/or viral RNA
positive. In contrast, all of 13 adult chimpanzees ages 14 to 45
years were SFVcpz infected (Figure 5). Thus, there was a
significant increase of SFVcpz infection with age, suggesting
horizontal rather than vertical (perinatal) transmission as the
predominant route of infection in these communities.
To investigate whether perinatal transmission was responsible for
at least some of the newly acquired infections, we tested longitudinal
samples from the three SFVcpz positive offspring and their infected
mothers. As shown in Table 5, Fansi (born in November 2001) was
fecal Western blot positive in June 2004 (2.6 years of age), but both
fecal antibodyand viralRNAnegativetwoyears earlierinAugust of
2002. Similarly, Flirt (born in July 1998) was fecal Western blot
positive in October 2001 (3.2 years of age), but antibody and viral
RNA negative one year earlier in November 2000. Although false
negative results at the earlier timepoints cannot be excluded, these
data suggest that the two infants acquired SFVcpz after their first
and third year of life, respectively. Analysis of the third mother/
offspring pair also failed to provide evidence for perinatal
transmission. Although Tarzan (born in October 1999) was SFVcpz
fecal antibody positive at the earliest timepoint (2.6 years of age) and
Table 3. Prevalence Rates of SFVcpz Infection in Wild Chimpanzees throughout Equatorial Africa.
Sites
a Subspecies
b
Samples tested
(WB/RT-PCR)
c
Samples positive
(WB/RT-PCR)
d
Chimpanzees
tested
e
Chimpanzees
infected SFVcpz Prevalence
f
TA P.t.v. 16 (16/16) 16 (16/7) 16 16 100 (83–100)
MF P.t.vl. 13 (13/13) 7 (0/7) –
h – 98 (59–100)
MP P.t.vl. 5 (5/5) 4 (2/4) – – 100 (22–100)
WE
g P.t.vl. 26 (26/13) 12 (8/9) – – 81 (55–97)
MT P.t.t. 81 (81/14) 32 (32/7) – – 79 (65–88)
DG P.t.t. 29 (29/29) 22 (4/22) – – 100 (81–100)
CP P.t.t. 10 (10/8) 6 (1/6) – – 100 (55–100)
DP
i P.t.t. 114 (114/52) 34 (22/19) 45 24 60 (47–73)
BQ P.t.t. 82 (82/21) 16 (9/10) – – 44 (31–58)
EK P.t.t. 19 (19/15) 8 (2/7) 15 8 66 (41–85)
BB P.t.t. 31 (31/18) 10 (1/10) 18 10 66 (44–84)
MB P.t.t. 25 (25/16) 10 (8/6) 18 8 54 (33–74)
LB P.t.t. 16 (16/8) 4 (1/4) 9 4 53 (23–81)
LP P.t.t. 13 (10/12) 9 (6/4) – – 100 (61–100)
GT P.t.t. 20 (20/20) 12 (11/5) 14 9 75 (50–90)
ME P.t.t. 21 (21/21) 16 (0/16) – – 100 (74–100)
BD P.t.s. 15 (15/15) 7 (2/7) – – 100 (65–100)
WL P.t.s. 22 (20/5) 8 (8/1) – – 73 (44–93)
WK P.t.s. 11 (10/4) 5 (4/3) – – 89 (44–100)
KB P.t.s. 27 (27/15) 14 (14/2) – – 98 (78–100)
NY P.t.s. 27 (27/18) 10 (6/4) – – 63 (37–85)
GM-KL P.t.s. 30 (30/3) 23 (23/2) 14 9 85 (61–97)
GM-MT P.t.s. 9 (6/7) 6 (4/2) 4 4 100 (47–100)
GM-KK P.t.s. 42 (33/33) 24 (16/12) 25 13 64 (46–80)
MH P.t.s. 20 (20/11) 11 (11/1) 17 9 75 (52–90)
n=25 724 (706/392) 326 (211/177) 195 114
aLocation of sites is shown in Figure 1.
bP.t.v., P. t. verus; P.t.vl., P. t. vellerosus; P.t.t., P. t. troglodytes; P.t.s., P. t. schweinfurthii.
cNumber of fecal samples tested for SFVcpz antibodies and/or viral RNA, with brackets indicating those tested by Western blot (WB) and those tested by RT-PCR,
respectively.
dNumber of fecal samples positive for SFVcpz antibodies and/or viral RNA, with brackets indicating those positive by WB and those positive by RT-PCR, respectively (the
phylogenetic relationships of these newly derived SFVcpz strains are depicted in Figures 6–8).
eFor four habituated communities (TA, GM-MT, GM-KK, MH) the number of tested chimpanzees was known; for seven non-habituated communities (GT, DP, EK, BB, MB,
LB, GM-KL) the number of tested chimpanzees was determined by microsatellite analysis of fecal DNA [33].
fFor sites where the number of chimpanzees was known, SFVcpz prevalence rates (%, with brackets indicating 95% confidence intervals) were estimated based on the
proportion of infected individuals, taking into account the ‘‘field sensitivities’’ of the antibody and virion RNA detection tests. For sites where the number of
chimpanzees was not known, prevalence rates were estimated based on the number of fecal samples tested, assuming that a fraction (17%) was partially degraded and
that any given chimpanzee was sampled on average 1.72 times (see Methods for details).
gBased on mtDNA analysis, 24 samples were of P. t. vellerosus and 2 of P. t. troglodytes origin.
h–; not available.
iFor this prevalence estimate, two WB indeterminant samples (reacting only with the Bet protein) were counted as negative.
doi:10.1371/journal.ppat.1000097.t003
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his mother’s, the same pol-IN sequences were also recovered from
three other chimpanzees, including Flirt and one unknown
individual from the neighboring Kalande community. Thus, it is
unclear whether Tarzan acquired his SFVcpz infection from his
mother during or shortly after birth, or whether he became infected
later by another route. Taken together, none of these three mother/
offspring pairs provided conclusive evidence for vertical transmis-
sion of SFVcpz in the wild.
SFVcpz evolution at the subspecies level
To determine the evolutionary relationships of SFVcpz strains
infecting wild chimpanzees in different parts of equatorial Africa,
we selected 392 fecal samples for RT-PCR analysis. Using primers
designed to amplify a conserved 425 bp pol-IN fragment [11–
13,18], we recovered SFVcpz sequences from 175 samples (one
sample yielded only LTR and another only pol-RT sequences; not
shown). Pol-IN sequences were also amplified from two P. t.
vellerosus apes housed in a Cameroonian sanctuary (SA161 and
SA163) as well as eight wild-living P. t. schweinfurthii apes who were
sampled at different locations within the Democratic Republic of
Congo (BA432, BF1167, EP479, EP486, KS310, UB446, WA466,
WA543; Figure 1). The phylogenetic relationships of these SFVcpz
sequences to each other and to subspecies specific SFVcpz
reference sequences from the database are shown in Figure 6.
The analysis revealed three well-defined SFVcpz clades for viruses
from P. t. verus, P. t. vellerosus, and P. t. schweinfurthii apes,
respectively, each supported with very high posterior probabilities.
In contrast, SFVcpz strains from P. t. troglodytes formed two distinct
(well-supported) groups in the maximum clade credibility (MCC)
tree: (i) one major group which comprised the great majority of the
newly identified P. t. troglodytes strains, and (ii) one minor group
which included only four strains from the Lope Reserve in Gabon
and which formed a sister clade to SFVcpz from P. t. schweinfurthii
(Figure 6). Since the placement of the Lope group apart from the
Figure 4. Inverse correlation of fecal antibody and viral RNA
detection at different field sites. Fecal viral RNA (x-axis) and
antibody (y-axis) detection sensitivities are plotted for field sites with
known numbers of infected chimpanzees (Table 2). The size of the circle
is directly proportional to the number of samples tested (results from
the three Gombe communities were combined). Color coding and
corresponding two letter codes are as in Figure 1. Test sensitivities are
significantly inversely correlated (P,0.001).
doi:10.1371/journal.ppat.1000097.g004
Table 4. Number of SFVcpz and SIVcpz Infections in Chimpanzee Communities Harboring Both Viruses.
Sites
a Chimpanzees tested
Infected only with
SFVcpz
Infected only with
SIVcpz
Co-infected with both
SFVcpz and SIVcpz Uninfected
DP 45 22 0 2 21
EK 15 6 2 2 5
MB 18 4 2 4 8
LB 9 3 1 1 4
GM-MT 4 3 0 1 0
GM-KK 25 12 1 1 11
GM-KL 14 5 1 4 4
n=7 130 55 7 15 53
aOnly collection sites with known numbers of infected individuals were included in this analysis.
doi:10.1371/journal.ppat.1000097.t004
Figure 5. Increase of SFVcpz infection rates with age. Members
of the habituated Mitumba and Kasekela communities in Gombe
National Park were non-invasively tested for SFVcpz infection and their
infection rate (y-axis) plotted by age group (x-axis). Group 1 comprises 4
infants age 2 or younger; group 2 comprises 10 chimpanzees age 2.1 to
9 years; and group 3 comprises 13 adult chimpanzees age 14 to 45.
doi:10.1371/journal.ppat.1000097.g005
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probability, we wondered whether its unexpected position in the
MCC tree might be due to the short length of the pol-IN (425 bp)
fragment. To clarify these relationships, we amplified additional
gag (616 bp) and pol-RT (717 bp) fragments from a subset of
samples. Indeed, phylogenetic analysis of these larger fragments
placed a representative of the ‘‘Lope variant’’ (LP29) together with
the other SFVcpzPtt strains within a single cluster. In the gag
region, this clade was supported with a highly significant posterior
probability (Figure 7). In the pol-RT region, where the posterior
probability was not high, the MCC tree nevertheless placed all P. t.
troglodytes sequences in a monophyletic clade (Figure 8). Moreover,
an analysis of combined pol-IN and pol-RT data (not shown)
yielded a monophyletic P. t. troglodytes SFVcpz clade, with 100%
posterior probability. Thus, SFVcpz strains from wild chimpan-
zees grouped into four major lineages according to their subspecies
of origin.
To examine further the evolution of SFVcpz at the subspecies
level, we obtained mitochondrial DNA sequences (hypervariable
D loop region) from all SFVcpz vRNA positive fecal samples and
performed a Bayesian Markov chain Monte Carlo (BMCMC)
phylogenetic analysis (Figure S1). The topology of this tree was
similar to previous mtDNA phylogenies in several key features
[33]: (i) P. t. verus and P. t. vellerosus as well as P. t. troglodytes and P. t.
schweinfurthii clustered together, forming two highly divergent
lineages; (ii) P. t. verus and P. t. vellerosus formed two well separated
sister clades; and (iii) P. t. schweinfurthii fell within the P. t. troglodytes
radiation. Comparison of this mtDNA phylogeny with those of
SFVcpz pol-IN, pol-RT and gag regions (Figures 6, 7, 8) revealed a
number of differences. Most notably, SFVcpz strains from P. t.
vellerosus were much more distant from SFVcpz strains infecting P.
t. verus than would have been predicted based on mtDNA
phylogenies of their respective hosts. In both gag and pol-RT trees,
P. t. vellerosus viruses shared a most recent common ancestor with
strains from P. t. troglodytes rather than with strains from P. t. verus
(as with the placement of the Lope strains, the gag pattern was
mirrored in the MCC tree from the pol-RT analysis, albeit without
significant support). In addition, SFVcpz from P. t. troglodytes apes
formed a single clade (Figures 7 and 8), while their corresponding
mtDNA sequences were paraphyletic, being separated by the P. t.
schweinfurthii clade (Figure S1). In many cases, chimpanzees with
highly divergent mtDNA haplotypes harbored closely related
SFVcpz strains, and vice versa. Finally, one fecal sample (WE464)
collected north of the Sanaga River contained SFVcpz sequences
from P. t. vellerosus, but mtDNA sequences from P. t. troglodytes
(boxed in Figures 6, 7, 8, S1). While the latter finding is most
simply explained by the migration of a P. t. troglodytes ape across the
Sanaga River some time in the past, followed by infection of her
progeny with the local variety of SFVcpz, the other discordances
are more difficult to interpret. It is clear that SFVcpz is not strictly
maternally inherited, since its evolutionary history shows differ-
ences with the mtDNA tree. Moreover, the mtDNA phylogeny
(Figure S1) offers only a limited perspective on the ancestral
relationships of chimpanzee populations, even setting aside any
possible inaccuracies due to the short fragment analyzed. Thus,
deciphering chimpanzee evolution in the more recent past will
require additional study. However, the fact that 120 naturally
occurring SFVcpz strains clustered in strict accordance with their
mtDNA-defined subspecies of origin provides compelling evidence
for virus-host co-evolution.
Table 5. SFVcpz Infection in Three Mother-Offspring Pairs in Gombe National Park.
Individual
a Date of Birth Age at Sampling (years) SFVcpz infection Relationship
fecal antibodies fecal vRNA
Fansi 11/02/01 0.8 neg neg son
Fansi 11/02/01 2.6 pos neg son
Fansi 11/02/01 2.7 nd
b neg son
Flossi 02/05/85 17.3 nd neg mother
Flossi 02/05/85 18.6 pos neg mother
Flossi 02/05/85 19.4 neg pol-IN mother
Flirt 07/20/98 2.4 neg neg daughter
Flirt 07/20/98 3.2 pos neg daughter
Flirt 07/20/98 3.8 nd pol-IN daughter
Fifi 07/02/58 44.6 pos neg mother
Fifi 07/02/58 45.1 neg nd mother
Fifi 07/02/58 45.2 pos neg mother
Tarzan 10/01/99 2.6 pos neg son
Tarzan 10/01/99 2.8 pos pol-IN son
Patti 07/02/61 40.5 nd pol-IN,gag mother
Patti 07/02/61 40.8 nd pol-IN, gag, pol-RT mother
Patti 07/02/61 42.1 pos neg mother
Patti 07/02/61 43.3 nd pol-IN, gag mother
Patti 07/02/61 43.5 nd pol-IN, gag mother
aAll individuals were members of the Mitumba and Kasekela communities.
nd; not done.
doi:10.1371/journal.ppat.1000097.t005
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PLoS Pathogens | www.plospathogens.org 9 July 2008 | Volume 4 | Issue 7 | e1000097Figure 6. Evolutionary relationships of newly derived SFVcpz strains in the pol-IN region. Pol-IN (425 bp) sequences were analyzed using
the Bayesian Markov chain Monte Carlo (BMCMC) method implemented in BEAST. Sequence LM183 (from a wild bonobo) was included as an
outgroup. The maximum clade credibility (MCC) tree topology inferred using TreeAnnotator v1.4.7 is shown, with branch lengths depicting the mean
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PLoS Pathogens | www.plospathogens.org 10 July 2008 | Volume 4 | Issue 7 | e1000097Figure 7. Evolutionary relationships of newly derived SFVcpz strains in the gag region. Gag (616 bp) sequences were analyzed as
described in Figure 6. The gag tree was rooted using a relaxed clock. Posterior probabilities are indicated on well-supported nodes, either as asterisks
(100%) or filled circles (90%–99%). Newly identified SFVcpz strains are color coded according to their subspecies of origin (Figure 1). Representative
strains from the database are shown in black. Plus signs (+) denote sequences that represent placeholders of multiple viruses with identical
sequences (Table S2). Sample WE464 (boxed) was collected in the P. t. vellerosus range, but has a P. t. troglodytes mtDNA haplotype (Figure S1). The
scale bar represents 0.02 substitutions per site.
doi:10.1371/journal.ppat.1000097.g007
value for that branch in the upper half of the MCMC sample. Posterior probabilities (expressed as percentages) are indicated on well-supported
nodes, either as asterisks (100%) or filled circles (90%–99%). Newly identified SFVcpz strains are color coded according to their subspecies of origin (as
shown in Figure 1). Representative strains from the database are shown in black. Plus signs (+) denote sequences that represent placeholders of
multiple viruses with identical sequences (a complete list is provided in Table S2). Sample WE464 (boxed) was collected in the P. t. vellerosus range,
but has a P. t. troglodytes mtDNA haplotype (Figure S1). Arrows identify distinct SFVcpz strains (termed A or B) that were found in the same sample.
The scale bar represents 0.02 substitutions per site.
doi:10.1371/journal.ppat.1000097.g006
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As shown in Figure 1, three of the four chimpanzee subspecies
were sampled at multiple locations. This provided an opportunity
to examine whether viruses from P. t. vellerosus, P. t. troglodytes and P.
t. schweinfurthii apes clustered according to their collection sites of
origin, as previously reported for SIVcpz [33,42]. Inspection of
Figures 6–8 revealed that this was generally not the case. Although
each of the major SFVcpz clades exhibited considerable structure,
the great majority of sublineages were comprised of viruses from
multiple field sites. Moreover, geographic distance did not predict
viral diversity. For example, viruses from the single DG field site in
southern Cameroon exhibited as much pol-IN inter-strain diversity
(0% to 5.8%) as did viruses collected hundreds of kilometers apart
at the CP and LB/MB field sites (0% to 4.1%). Nonetheless, there
were some notable exceptions. Significant geographic clustering
was observed for (i) P. t. troglodytes viruses from the ME and GT
field sites in the Central African Republic and the Republic of
Congo (Figures 6, 7, 8); (ii) P. t. troglodytes viruses from the LP field
site in Gabon (Figure 6); and (iii) P. t. schweinfurthii viruses from the
BD field site in the Democratic Republic of Congo (Figure 6).
Figure 8. Evolutionary relationships of newly derived SFVcpz strains in the pol-RT region. Pol-RT (718 bp) sequences were analyzed as
described in Figure 6. The tree was rooted using LM183 as an outgroup. Posterior probabilities are indicated on well-supported nodes, either as
asterisks (100%) or filled circles (90%–99%). Newly identified SFVcpz strains are color coded according to their subspecies of origin (Figure 1). One
representative strain from the database (HFV) is shown in black. Plus signs (+) denote sequences that represent placeholders of multiple viruses with
identical sequences (Table S2). Sample WE464 (boxed) was collected in the P. t. vellerosus range, but has a P. t. troglodytes mtDNA haplotype (Figure
S1). Arrows identify distinct SFVcpz strains (termed A or B) that were found in the same sample. The scale bar represents 0.02 substitutions per site.
doi:10.1371/journal.ppat.1000097.g008
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chimpanzee movement. GT and ME were the only P. t. troglodytes
field sites east of the Sangha River; LP was separated from all
other P. t. troglodytes sites by the Ogooue River; and BD was the
only P. t. schweinfurthii collection site north of the Uele River
(Figure 1). Thus, in addition to delineating the subspecies ranges,
major rivers and other biogeographical barriers appear to also
have influenced the dispersal of SFVcpz within existing subspecies
ranges.
SFVcpz co-infection and recombination
GENECONV analyses and inspection of phylogenetic trees
inferred for each independently amplified gene fragment
(Figures 6, 7, 8) identified several SFVcpz strains with a strong
signal of distinct evolutionary histories in different parts of their
genome. For example, MF1269 was most closely related to other
MF strains in gag and pol-RT regions (Figures 7 and 8), but
clustered with MP and WE viruses in the pol-IN region (Figure 6).
Such discordant branching patterns can be indicative of viral
recombination but also of co-infection with divergent viruses [44–
47]. Similarly, DG534, DP157, and CP470 were all found by
GENECONV to be members of sequence pairs with globally
significant (P,0.05) evidence of mosaic evolution. In the case of
DG534 and DP157, highly significant putative recombination
breakpoints were detected at or near the junction of independently
amplified sequence fragments, strongly suggesting that some were
due to the amplification of two or more variants from the same
sample rather than intramolecular recombination per se.
To differentiate between these possibilities, we selected five such
samples (DG534, DP157, MF1279, MF1269, CP470) for
additional RNA extraction, RT-PCR and sequence analyses.
Comparison of independently amplified gag, pol-IN, and pol-RT
sequences yielded unequivocal evidence of SFVcpz co-infection in
three of the five fecal samples. As shown in Figures 6 and 8, DP157
harbored two clearly distinct variants (DP157A and DP157B). The
observation that these sequences fall into different, highly
supported clades (P=1.0) within the P. t. troglodytes SFVcpz
radiation leaves little doubt that this chimpanzee was co-infected
with more than one strain. The alternative, i.e., that the divergent
sequences trace back to a single infection that diversified
extensively within a single chimpanzee, is inconsistent with the
fact that sequences from other apes are interspersed between the
DP157 variants. Similarly, DG534 and MF1279 each exhibited (at
least) two distinct SFVcpz strains as determined by phylogenetic
analysis of independently amplified (and directly sequenced) pol-
RT sequences (Figure 8). To follow up on these observations, we
subjected two of these samples (DP157 and MF1279) to single
genome amplification (SGA). This approach amplifies single viral
templates, precludes Taq polymerase errors and in vitro recombi-
nation, and provides an accurate representation of the viral
population in vivo [48–50]. Targeting both pol-IN (Figure 9A) and
pol-RT regions (not shown), we generated SGA derived sequences
for MF1279 and DP157. Phylogenetic analysis of these sequences
confirmed co-infection of MF1279 with two SFVcpz strains, and
revealed the presence of at least four distinct SFVcpz strains in
DP157 (Figure 9A).
In contrast, re-amplification experiments indicated that
MF1269 and CP470 each harbored only a single identifiable
virus. To determine whether MF1269 was truly mosaic, we first
used GENECONV to examine its concatenated gag, pol-RT and
pol-IN sequences for evidence of recombination. Pairwise analyses
identified a potential recombination breakpoint in MF1269 near
the pol-IN/pol-RT overlap (although this comparison fell margin-
ally below significance according to the global P-value, which is
corrected for multiple comparisons). We then amplified the
corresponding pol fragment as a single genetic unit (Figure 3).
The resulting L-pol sequence was identical to the concatenated
MF1269 pol-IN and pol-RT sequences, indicating that the
apparent signal of recombination could not be explained, in this
case, by co-infection. Moreover, SGA amplification of the
MF1269 L-pol fragment (which yielded four amplicons that
differed from each other and the direct sequence by two or less
nucleotide substitutions) excluded the possibility that the recom-
bination breakpoint was a Taq polymerase induced PCR artifact
[48]. Given the GENECONV evidence and more importantly, the
100% posterior probability support for MF1269 clustering on a
different P. t. vellerosus SFVcpz lineage in pol-IN than in gag or pol-
RT (Figures 6, 7, 8), we concluded that this sequence is a bona fide
SFVcpz recombinant.
The CP470 case offered perhaps even stronger evidence of
natural SFVcpz recombination. Having confirmed by repeated
amplifications that this sample was not coinfected, we observed
that the most parsimonious explanation for its inclusion by
GENECONV in a sequence pair with a globally significant
fragment (P,0.03) was that it was a ‘‘parent’’, rather than a
‘‘daughter’’ (recombinant) sequence. GENECONV identified
EK522 as the other sequence in the pair. Figure 9B indicates
that it is this sequence and its close relatives (EK511, EK505,
EK506) that appear to move from being closely related to CP470
(as well as MB191 and MB318) upstream of the identified
breakpoint, to sharing a most recent common ancestor with the
clade of ME viruses downstream of the breakpoint. We did not
seek to reproduce the observed breakpoints in the EK clade
because the fact that the sequences move across the tree together
straightforwardly indicates that they evolved from a common
recombinant ancestor.
It is worth noting that EK522 was the only one of this group
with a globally significant P-value when compared with CP470;
the other EK sequences all had highly significant pairwise P-
values, but non-significant global values. Since they are all clearly
closely related, this indicates that the global P-values represent a
rather conservative measure of statistical significance for recom-
bination in SFVcpz. It is thus highly likely that several of the
numerous fragments that were significant in pairwise, but not
global GENECONV comparisons also reflect recombination (data
available upon request). Indeed, the strong phylogenetic evidence
for recombination in MF1269 indicates that this is the case. Taken
together, these results show for the first time that chimpanzees can
be superinfected by different SFVcpz strains and that such
superinfection can lead to recombination. They also suggest that
recombination may occur rather frequently in SFVcpz.
Cross-species transmission of SFV
Chimpanzees are avid hunters and frequently prey on smaller
monkeys [51–53]. Since exposure to primates through hunting
promotes acquisition of SFV by humans [10,28], we wondered
whether this was also the case in chimpanzees. Using conserved
pol-IN primers previously shown to amplify divergent SFV strains
[11–13,18], we uncovered one simian foamy virus that did not fall
within the SFVcpz radiation (Figure 10). This virus, termed
LB309, was identified in a male member of a group of nine P. t.
troglodytes apes sampled at the LB field site [33]. Phylogenetic
analysis indicated that this unusual virus was most closely related
to SFV strains previously identified in captive DeBrazza’s
(Cercopithecus neglectus) and mustached (Cercopithecus cephus) monkeys
housed in an African primate facility (W. Switzer, unpublished).
Since LB309 was identified in only a single fecal sample, we
considered the possibility that it represented a mixture of
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previous host genetic studies had yielded unambiguous microsat-
ellite, sex and mtDNA data (Table S2 in [33]) rendered this
scenario highly unlikely. We also looked for co-infection with
chimpanzee foamy virus since four other chimpanzees from the
LB site harbored SFVcpz (Table 3; Figure 6); however, repeated
Figure 9. Coinfection and recombination in SFVcpz. (A) The maximum clade credibility (MCC) topology of pol-IN sequences is shown, with
branch lengths as described in Figure 6. Brackets indicate the number of distinct SFVcpz strains that are present in samples DP157 and MF1279,
respectively. Bulk PCR derived sequences are shown in red; SGA derived sequences are shown in blue. Numbers on nodes indicate posterior
probabilities expressed as percentages (only values of 90% or higher are shown). The scale bar represents 0.009 substitutions per site. (B) Maximum
clade credibility (MCC) topologies of gag sequences in two adjacent fragments are shown. Viruses that exhibit discordant branching patterns are
highlighted. Numbers on nodes indicate percentage posterior probabilities. The scale bars represent 0.02 substitutions per site.
doi:10.1371/journal.ppat.1000097.g009
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suggested LB309 was the only (productively) infecting SFV strain.
Although the species origin of LB309 could not be determined,
this represents the first documented case of a monkey-to-ape
transmission of SFV in wild P. t. troglodytes apes.
Discussion
A primary objective of this study was to explore whether non-
invasive detection methods previously developed for SIV could be
adapted to the identification of other infectious agents in
endangered primates. We selected SFV infection of wild
chimpanzees as a test case for several reasons: First, SFVs can
infect humans who come in contact with primates and may thus
represent suitable markers of human zoonotic exposure risks
[8,10,13,19,24–28]. Given that chimpanzees are naturally infected
with several known human pathogens [33,54,55], determining the
prevalence and genetic diversity of SFVcpz represented a first step
toward examining the utility of this virus as a sentinel for human
zoonoses. Second, although seemingly non-pathogenic in natural
and non-natural hosts, SFVs could alter the course of SIV and
HIV infections since dual SFV/HIV infections have been
documented both in sex worker and blood donor cohorts in
Africa [22,56]. Thus, screening chimpanzees for both infections
provided an opportunity to examine whether SIVcpz and SFVcpz
are epidemiologically linked. Finally, foamy viruses are being
explored as vaccine and gene therapy vectors for various human
diseases [57–59]. It thus seemed prudent to study at least one
member of this virus group in its natural host. To this end, we
developed new SFVcpz specific fecal detection methods and used
these to conduct a large-scale molecular epidemiological survey of
wild chimpanzees throughout equatorial Africa. Our results
indicate that non-invasive screening strategies can be extended
to other infectious agents and show more generally how
endangered primates can be studied by non-invasive molecular
approaches.
Although both SIVcpz and SFVcpz infected chimpanzees
secrete antibodies and nucleic acids into their feces, we found
marked differences in the detection sensitivities of these viral
markers between the two infections. The most striking difference
was the extreme variability with which fecal antibodies and/or
viral RNA were detected in SFVcpz infected apes from different
communities (Table 2). For example, at the TA and MH field sites
nearly all SFVcpz infected chimpanzees were antibody positive
(Western blot sensitivities of 100% and 92%, respectively), but
only very few had detectable viral RNA in their feces (44% and
9%, respectively). In contrast, at the BB and LB field sites nearly
all SFVcpz infected chimpanzees were vRNA positive (100% and
80%, respectively), but only very few had detectable antibodies in
their feces (8% and 13%, respectively). A comparison of test
sensitivities across all field sites indicated that these values were
inversely correlated (Figure 4). To determine whether this was due
to a technical artifact, we re-analyzed nearly 300 antibody
negative samples (including 74 specimens containing SFVcpz
RNA) using newly produced Western blot strips and freshly
prepared fecal extracts. Except for 17 weakly reactive samples, all
others remained antibody negative. We also analyzed 34 IgG
negative fecal samples for the presence of SFVcpz specific IgA.
Figure 10. Cross-species transmission of SFV in the wild. The maximum clade credibility (MCC) topology of pol-IN sequences is shown, with
branch lengths as described in Figure 6. The chimpanzee SFV strain LB309 (red box) significantly clusters within a group of SFVs previously derived
from captive L’Hoest’s (LHO), Hamlyn’s (HAM), mustached (MUS), DeBrazza’s (DEB), mona (MON), Sykes’s (SYK) and blue (BLU) monkeys (GenBank
accession numbers are indicated in parentheses), thus strongly suggesting a Cercopithecus monkey origin. Newly derived SFV sequences from a
bonobo (LM183), gorilla (LP5), mandrill (LP47) and DeBrazza’s monkey (CNE01) are also shown (blue) in relation to reference sequences from
Chlorocebus and Mandrillus species (black). Numbers on nodes indicate posterior probabilities expressed as percentages (only 90% or higher are
shown). The scale bar represents 0.08 substitutions per site.
doi:10.1371/journal.ppat.1000097.g010
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specific IgA in other chimpanzee mucosal compartments [60].
Finally, we repeated RT-PCR analysis on a select number of RNA
negative samples, but failed to uncover new SFVcpz sequences.
Thus, the observed differences in fecal antibody and vRNA
detection sensitivities cannot be explained by uneven test
performance. Instead, SFVcpz infected chimpanzees appear to
shed virus specific antibodies and nucleic acids only intermittently.
Whether these fluctuations reflect true temporal differences in
fecal antibody secretion and virus replication, or are the
consequence of generally lower production levels that sometimes
fall below the limits of detection, will require further study.
However, in light of the data in Figure 9, it is tempting to speculate
that the observed inverse correlations reflect, at least in part,
different stages of recurring SFVcpz superinfection cycles where
high titer viral replication at mucosal sites elicits an effective
humoral (and possibly also cellular) immune response which
reduces fecal viral load until the next infection cycle ensues.
Regardless of the underlying mechanism(s), the observed fecal
antibody and viral RNA fluctuations are in stark contrast to
chronic SIVcpz infection where fecal antibodies are detected at all
times with high sensitivity (92%), and where vRNA is amplified
from virtually all antibody positive (non-degraded) fecal samples
especially when different PCR primer sets are used [33,42]. Thus,
a screening algorithm consisting of an initial fecal antibody test
followed by RT-PCR of only antibody positive samples (which is
the standard approach for non-invasive SIVcpz surveys) is clearly
not suitable for molecular epidemiological studies of SFVcpz.
Instead, reliable non-invasive SFVcpz prevalence estimates require
the use of both vRNA and antibody detection tests.
SFV infection is latent in most tissues, except for lung and
tissues of the oral pharynx which express large quantities of viral
RNA (up to 10
4 copies per cell) and thus represent primary sites of
SFV replication [20–22]. SFV replication has also been observed
in the mesenteric lymph nodes and small intestine of SIVmac
infected macaques [22]; however, even in these severely immune
compromised animals, there was no evidence of SFV replication in
the large intestine [22]. In light of these data, our finding of
SFVcpz RNA in a large number of fecal samples comes as a
surprise. Passage through the stomach would be expected to
degrade both cell and virion associated SFVcpz RNA. It is thus
highly unlikely that the fecal RNA that we observe is produced in
the oral mucosa. Instead, it seems more likely that gut epithelial
cells represent a primary site of SFV replication, at least at some
stage during natural infection. Given the apparent fluctuations in
fecal RNA shedding, it is easy to envision how this could have
previously gone unrecognized [22]. We did not determine the
copy number of SFVcpz RNA in the feces and thus cannot
estimate how many cell equivalents are required to account for the
detected amounts. However, in addition to SFVcpz, we also
amplified SFV RNA from a limited number of bonobo, gorilla and
mandrill stool samples, all of which were collected in the wild
(Figure 10). It is thus clear that fecal RNA shedding is a common
property of this entire group of viruses. It will be interesting to
determine whether SFV RNA containing stool samples are
infectious. This could explain why some zoo workers and animal
handlers who never had direct physical contact with non-human
primates were found to be SFV infected [8,19].
In addition to its production site, the source of the SFVcpz RNA
in stool samples remains a mystery. Unlike in other retroviruses,
reverse transcription of the SFV genome takes place during
budding and virion assembly, resulting in the production of SFV
particles that contain both viral DNA and RNA [39,40]. The viral
RNA that we detect may thus derive from cell free virions and/or
from mRNA and genomic RNA present in productively infected
cells that are sloughed off into the feces. However, since SFV
particles often bud at intracellular membranes [61], we would
expect to also detect viral DNA. Instead, we found SFVcpz DNA
in only 2 of 40 fecal samples from captive chimpanzees, and in
none of 173 samples (including 87 SFVcpz RNA positive
specimen) from wild chimpanzees. Thus, it remains unknown
whether the SFVcpz RNA present in fecal samples is cell-derived,
particle-derived, or a combination of both. Given our findings, it
may also be of interest to determine whether currently used in vitro
culture systems accurately reflect SFV replication in vivo.
Our survey of 25 different chimpanzee communities revealed
high prevalence rates of SFVcpz infection across equatorial Africa.
This observation, together with the lack of geographic clustering of
most SFVcpz strains, and the obvious propensity of SFVcpz to
superinfection and recombination, indicates that SFVcpz is a
highly transmissible virus. Previous studies have indicated
horizontal routes as the primary mode of SFV transmission
[2,17,62]. Our findings in Gombe National Park are consistent
with these observations. The fact that we detected SFVcpz in each
of 13 adult chimpanzees, but in only 3 of 14 infants and juveniles
indicates a clear increase of SFVcpz prevalence with age. In
addition, we found no conclusive evidence for perinatal transmis-
sion. Two of the three infected offspring were SFVcpz negative at
the time of first analysis, and the third one harbored a virus that
was genetically indistinguishable in the pol-IN region from viruses
infecting unrelated chimpanzees. Thus, perinatal transmission of
SFVcpz, if it occurs at all, appears to be uncommon in wild-living
chimpanzees. Instead, chimpanzees appear to acquire SFVcpz by
horizontal routes, most likely by exposure to saliva (or feces), as has
been proposed for other primates [17,20,62]. Indeed, young
chimpanzees stay with their mothers until they are 8 or 9 years old
and often share food. Thus, infants and juveniles are frequently
exposed to their mother’s saliva, which may constitute a common
source of infection. In contrast, SIVcpz appears to be transmitted
primarily by sexual (and sometimes perinatal) routes ([37]; Keele
et al., unpublished). In light of these differences, the absence of an
epidemiological link between SIVcpz and SFVcpz infections is
perhaps not too surprising. Examining seven different communi-
ties, we found no indication that infection with one of these viruses
increased or decreased the likelihood of infection by the other.
Simian foamy viruses are believed to have co-evolved with their
respective primate hosts for millions of years [13], and our finding
of subspecies-specific SFVcpz lineages is consistent with this
hypothesis. Remarkably, all of the 120 newly characterized
SFVcpz strains clustered according to their subspecies of origin.
This included one strain from a site (WE) just north of the Sanaga
River (i.e., within the range of P. t. vellerosus) infecting an individual
with P. t. troglodytes mtDNA, indicating gene flow, but not viral
flow, across a subspecies boundary. This monophyly of SFVcpz
strains from each subspecies contrasts with the mtDNA phylogeny
where P. t. schweinfurthii sequences lie within the P. t. troglodytes
radiation. While the validity of classifying chimpanzees into
subspecies has been questioned [63], the SFVcpz phylogeny
corroborates the existence of four geographically isolated chim-
panzee populations and the absence of SFVcpz transmission
between subspecies argues that they are effectively separated,
especially since such transmissions are frequently observed in
captive settings (e.g., see DEB and MUS SFVs in Figure 10). The
SFVcpz and mtDNA phylogenies (Figures 6, 7, 8, S1) differed with
regard to the relationships among the four subspecies. However,
these differences do not undermine the co-evolution hypothesis.
When successive speciation events occur over a relatively short
timescale, persistence of polymorphism from one event to the next
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phylogeny as the species [64]; this phenomenon is even more likely
with recent subspeciation events. Thus, even if there has been
complete co-evolution of SFVcpz with chimpanzees, discordance
between the SFVcpz and mtDNA phylogenies may appear
because either, or both, differ from the true historical relationships
among the subspecies. In fact, the apparently shorter coalescence
time of SFVcpz indicated by the reciprocal monophyly of P. t.
troglodytes and P. t. schweinfurthii viruses suggests that SFVcpz could
be less susceptible to this problem than mtDNA. Thus, SFVcpz
may emerge as a more sensitive marker of population structure
that may be useful for chimpanzee systematics as well as
conservation strategies.
Phylogenetic analyses identified discordant branching orders for
several SFVcpz strains, suggesting co-infection or recombination
[44–47]. To examine whether this was indeed the case, we selected
a subset of samples for repeat RT-PCR analyses, including single
genome amplification (SGA) of re-extracted fecal viral RNA. SGA
amplifies single viral templates, is not subject to Taq polymerase
induced nucleotide substitutions and recombination, and thus
provides an accurate representation of the viral population in the
individual [48–50]. Adapting this approach to fecal RNA provided
new insights into SFVcpz biology. SGA analysis formally
documented infection with more than one virus in two
chimpanzees. One of these apes (MF1279) was infected with two
distinct SFVcpz strains, while the other (DP157) harbored at least
four genetically diverse viruses. In both cases, predominant viral
forms were identified by bulk RT-PCR (red in Figure 9A), but
SGA was required to characterize the full extent of viral diversity
in the sample, including the relative proportion of different
variants. Repeat RT-PCR and SGA analyses also documented
mosaic genome structures in several SFVcpz strains and
demonstrated that these did not represent PCR artifacts. Although
preliminary, these results suggest that superinfection and recom-
bination occur rather frequently. As mentioned above, successive
superinfection cycles may account at least for some of the observed
fluctuations in fecal antibody and viral RNA detection in different
chimpanzee communities. It will be interesting to test this
hypothesis in chimpanzees from Gombe National Park where
longitudinal samples from SFVcpz infected apes are available.
Because they are avid hunters, chimpanzees are also frequently
exposed to SFV strains from other primate species. Testing 392
fecal samples for SFVcpz viral RNA, we found one male
chimpanzee to harbor an SFV strain (LB309) that was closely
related to viruses previously identified in captive DeBrazza’s and
mustached monkeys (Figure 10). The finding of LB309 RNA
indicated a productive viral infection in the chimpanzee host.
Similar findings were recently reported for chimpanzees from the
Taı ¨ Forest where 3 of 12 apes studied harbored SFV strains from
sympatric western red colobus monkeys [65]. Interestingly, these
apes (all males) were also coinfected with SFVcpz; however, it was
not determined whether the dual infections were productive since
viral DNA (and not RNA) sequences were amplified from spleen
necropsy specimens using strain specific PCR primers [65]. Since
we did not use strain specific primers, it is likely that our data
grossly underestimate the frequency of SFV cross-species trans-
mission in the wild. Moreover, the failure of these cross-species
infections to initiate secondary spread suggests that their
replication (and thus fecal detection) may be limited. However,
the examples demonstrate that chimpanzees, like humans, are
susceptible to SFVs from other primate species, and the fact that
all cross-infected apes were males (who hunt more frequently and
eat more meat than females) strongly suggest that these
transmissions occur in the context of predation. These findings
may be of use to primatologists interested in chimpanzee hunting
behavior and prey preferences in the wild.
Finally, SFVs are of public health interest because people in
sub-Saharan Africa are routinely exposed to these viruses in the
context of primate bushmeat hunting [10,28]. We show herein
that SFVcpz infection is highly prevalent in wild chimpanzee
populations throughout their natural range. Thus, monitoring
humans for SFVcpz infection should be informative as to the
locations where human/chimpanzee encounters are most frequent
and where additional cross-species transmissions should be
anticipated. One such area is southern Cameroon where
chimpanzees are endemically infected with SIVcpz strains that
have already crossed the species barrier to humans, in one case
(HIV-1 group M) with devastating consequences [33]. Screening
humans for SFVcpz infection may also provide new insight into
the environmental circumstances that underlie cross-species
transmissions. For example, if the frequency of human SFVcpz
infection were significantly lower in east compared to west central
Africa, this would argue for lower exposure rates and, in turn,
provide a reason why SIVcpz strains from P. t. schweinfurthii apes
have not emerged as human pathogens. Thus, human SFVcpz
infection should be formally investigated a sentinel for ape-derived
pathogens, including new SIVcpz/HIV-1 outbreaks.
Methods
Captive chimpanzees
Fecal samples (n=40) were collected from 23 captive chim-
panzees housed at the Yerkes National Primate Research Center
(Table 1), all of whom were known to be chronically infected with
SFVcpz [8,66]. Fecal samples were also obtained from nine P. t.
vellerosus apes housed in a Cameroonian sanctuary (SA) who were
of unknown SFVcpz infection status. Samples were preserved in
RNAlater, shipped and processed as described [33,37]. All studies
were carried out in strict accordance with international guidelines
for the ethical scientific use and humane care of primates in
research (the Yerkes National Primate Research Center is fully
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International).
Human volunteers
Blood and fecal samples were collected from 21 human
volunteers who had no previous contact with primates or primate
tissues (informed consent was obtained and the study protocol was
approved by the University of Alabama at Birmingham Commit-
tee for Human Research). All of these individuals were
seronegative for SFVcpz antibodies as determined by Western
blot analysis (Table 1).
Wild chimpanzees
The fecal samples (n=732) used in this study were selected from
existing banks of specimens previously collected for molecular
epidemiological studies of SIVcpz [33,37,67,68]. The great
majority (n=724) were collected from chimpanzee communities
in Cote d’Ivoire, Cameroon, the Central African Republic (CAR),
Gabon, the Republic of Congo (RC), the Democratic Republic of
Congo (DRC), Uganda, Rwanda, and Tanzania (white circles in
Figure 1). Eight additional samples (BA432, BF1167, EP479,
EP486, KS310, UB446, WA466, WA543) were collected at
various locations in the DRC (black circles in Figure 1). All
samples were collected in the wild, and their species and subspecies
origin were confirmed by mitochondrial DNA analysis. All
samples were also screened for SIVcpz antibodies and/or nucleic
acids. Of the 732 samples, 87 were collected from habituated
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of the North and South communities in the Taı ¨ Forest (TA), Cote
d’Ivoire [69], the Mitumba and Kasekela communities in Gombe
National Park (GM-MT, GM-KK), Tanzania [43,70], and the M
group in Mahale Mountains National Park (MH), Tanzania [71].
At seven additional field sites, the number of sampled individuals
was retrospectively determined by microsatellite analysis [33].
These included the DP, EK, LB, MB and BB field sites in southern
Cameroon, the non-habituated Kalande (GM-KL) community in
Gombe National Park, and a site in the Goualougo Triangle (GT),
Republic of Congo [72]. At the remaining locations, the number
of sampled chimpanzees remained unknown. These included the
MF, MP, WE, MT, DG, BQ and CP field sites in Cameroon, the
ME site in the Central African Republic, a site in the Lope
National Park (LP) in Gabon, the BD, WL and WK field sites in
the DRC, and a site in the Nyungwe Forest Reserve (NY) in
Rwanda. Finally, samples were also obtained from the Ngogo
community in Kibale National Park (KB). Although the Ngogo
chimpanzees are habituated [52], the particular individuals
sampled for this study were not identified.
Other primates
Fecal samples were also obtained from a wild-living gorilla (LP5)
and mandrill (LP47) in the Lope National Park as well as a wild-
living bonobo (LM183) in the DRC. The species origin of these
samples was confirmed by mtDNA analysis (Table S2). In
addition, SFV pol-IN sequences were amplified from uncultured
PBMC DNA from a wild-caught DeBrazza monkey (99CM-
CNE1) previously reported to also harbor SIVdeb [73].
Detection of SFVcpz specific antibodies in fecal extracts
Fecal samples were examined for the presence of SFVcpz
specific antibodies using an enhanced chemiluminescent Western
immunoblot assay modified for RNAlater preserved specimens as
described [33]. RNAlater is a high salt solution (25 mM Sodium
Citrate, 10 mM EDTA, 70 g ammonium sulfate/100 ml solution,
pH 5.2) that preserves nucleic acids, but precipitates proteins,
including immunoglobulin. To prepare extracts suitable for
Western blot analysis, fecal/RNAlater mixtures (1.5 ml) were
diluted with PBS-Tween-20 (8.5 ml), inactivated for 1 hr at 60uC,
clarified by centrifugation (35006g for 30 min) to remove solid
debris, and then dialyzed against PBS overnight at 4uCt o
resuspend fecal immunoglobulin. Reconstituted extracts were
subjected to immunoblot analysis using SFVcpz antigen contain-
ing strips.
For Western blot strip preparation, an infectious SFVcpz
proviral clone (pMod-1) was transfected into BHK21 cells and the
resulting virus expanded in Cf2Th cells [61,74]. Briefly, Cf2Th
cells (2610
6 cells per 150 mm dish) were inoculated using a
multiplicity of infection of 0.1, harvested at 75–100% CPE,
pelleted, and resuspended in PBS (30 ml). Virions were released
from cells by repeated freezing and thawing (4 cycles), purified by
ultracentrifugation through a 20% sucrose cushion (23,5006g,
2 hrs), analyzed for protein content using a protein assay kit
(Pierce, Rockford, Ill.), denatured in Reducing Sample Buffer
(Piece, Rockford, Ill.), boiled, and run on a 7.5% Criterion Ready
Gel (BioRad, Hercules, Calif.). Proteins were transferred to
polyvinylidene difluoride (PVDF) membranes (BioRad, Hercules,
CA), which were cut into strips (4 mm width), incubated with
blocking buffer (5% nonfat dry milk, 3% fetal bovine sera, 0.5%
Tween-20 in PBS), and then reacted overnight at 4uC with fecal
extracts as described [33]. Protein-bound antibody was detected
with goat-anti-human IgG-HRP (Southern Biotech, Birmingham,
AL) and Western blots were developed using an enhanced
chemiluminescence (ECL) detection system (GE Healthcare Bio-
Sciences, Piscataway, NJ).
Amplification of SFVcpz sequences from fecal nucleic
acids
Fecal RNA was extracted using the RNAqueous-Midi kit
(Applied Biosystems/Ambion, Austin, TX) and subjected to
reverse transcriptase polymerase chain reaction (RT-PCR)
amplification using different sets of SFVcpz specific primers. In
each case, cDNA was synthesized using the outer reverse primer
(R1), followed by nested PCR using forward (F1/F2) and reverse
(R1/R2) primers. Fecal DNA was extracted using the QIAamp
DNA Stool Mini Kit (Qiagen, Valencia, CA) and subjected to
nested PCR. Previously described sets of nested primers were used
to amplify subgenomic pol-IN (425 bp), gag (616 bp) and LTR
(260 bp) regions [8,10–13,18]. In addition, nested pol-RT primers
were designed to amplify a 717 bp reverse transcriptase (RT)
fragment that extended the pol-IN fragment by 580 bp to the 59
end (F1: 59-AGCAGGATATGTAAGATATTATAATGA -39;
R1: 59-TCTCATATTTGGCCACCAATAAAGG -39 F2: 59-
TTTCATTATGATAAAACCTTACCAGAA -39; R2: 59-
TCCGGTGTGAGCCAAATTGTGGGCTTG -39). For a subset
of samples, we also used forward pol-RT primers in combination
with reverse pol-IN primers to amplify a 1,005 bp L-pol fragment.
The positions of these primers in the SFV genome are shown in
Figure 3. PCR conditions included 60 cycles of denaturation
(94uC, 20 s), annealing (50uC, 30 s), and elongation (68uC, 1 min)
for the first round. Second round conditions included 55 cycles of
denaturation (94uC, 20 s), annealing (52uC, 30 s), and elongation
(68uC, 1 min). Amplified products were gel purified (Qiagen) and
sequenced directly without interim cloning. Population sequences
were analyzed using Sequencher version 4.6 (Gene Codes
Corporation, Ann Arbor, MI) and chromatograms were carefully
examined for positions of base mixtures.
Single genome amplification of SFVcpz sequences
For a subset of samples suspected to harbor SFVcpz
recombinants or mixtures of distinct viral strains, the complexity
of the SFVcpz viral population within individual hosts was
independently analyzed by single genome amplification (SGA).
Fecal RNA was extracted from additional aliquots and cDNA
synthesized as described above. cDNA was endpoint diluted in 96-
well plates such that fewer than 29 reactions yielded an
amplification product. According to a Poisson distribution, the
cDNA dilution that yields PCR products in no more than 30% of
wells contains one amplifiable cDNA template per positive PCR
more than 80% of the time. PCR conditions and primers were as
described above. All amplicons were sequenced directly, and
sequences with ambiguous positions excluded from further
analysis.
Sensitivity and specificity of SFVcpz antibody and nucleic
acid detection
The sensitivities of SFVcpz antibody and viral nucleic acid
detection were determined for captive (YK) as well as wild-living
chimpanzees (TA, DP, EK, BB, MB, LB, GT, GM, MH) of known
SFVcpz infection status. Captive chimpanzees were diagnosed as
SFVcpz infected by demonstrating virus specific antibodies in their
blood (Tables 1 and 2). Wild-living chimpanzees were identified as
SFVcpz infected by demonstrating virus specific antibodies or viral
RNA in at least one fecal sample (Table 2). For each site,
sensitivities were calculated as the fraction of positive tests per total
number of samples tested, with confidence limits determined given
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assumed that successive test results from the same individual were
not correlated. The specificity of fecal antibody detection was
calculated using test results from SFVcpz antibody negative
human volunteers (Table 1) and determined to be 1.00 (0.87–
1.00). The specificities of vRNA and vDNA detection in fecal
samples were also 1.00, since all amplification products were
sequence confirmed.
SFVcpz prevalence estimations
For sites where the number of sampled chimpanzees was known
(TA, DP, EK, BB, MB, LB, GT, GM-KL, GM-MT, GM-KK,
MH), SFVcpz prevalence rates were estimated based on the
proportion of infected individuals. For each chimpanzee, the
probability that it would be detected as being infected, if it was
truly infected, was calculated taking into consideration the
sensitivities of the types of assays performed as well as the
numbers of specimens analyzed. Since the sensitivities of antibody
and viral RNA detection varied extensively between captive and
wild chimpanzees as well as different collection sites (Table 2), test
sensitivities were averaged across all field sites. These ‘‘field
sensitivities’’ were then used to calculate SFVcpz prevalence rates,
with 95% confidence limits determined based on binomial
sampling.
For field sites where the number of sampled individuals was not
known (MF, MP, WE, MT, DG, CP, BQ, LP, ME, BD, WL, WK,
KB, NY), prevalence rates were estimated based on the number of
fecal samples collected and tested. Based on results from previous
field studies [33], it was assumed that a fraction (17%) of all fecal
samples was partially degraded and that any given chimpanzee
was sampled on average 1.72 times. Using these corrections, the
proportion of SFVcpz infected chimpanzees was estimated for
each field site, again taking into account the ‘‘field sensitivities’’ of
the different tests as well as the numbers of specimens analyzed. In
addition, the number of unique mtDNA haplotypes served as an
indicator of the minimum number of chimpanzees analyzed. From
these determinations, prevalence rates and their confidence limits
were calculated.
Species and subspecies determinations
The species and subspecies origin of all chimpanzee fecal
samples used in this study was determined by mitochondrial (mt)
DNA analysis (Table S1). A 498-bp region of the mtDNA genome
(D loop) was amplified using primers L15997 (59-CACCATTAG-
CACCCAAAGCT-39) and H16498 (59-CCTGAAGTAGGAAC-
CAGATG-39), and all amplification products were sequenced
directly. The resulting sequences were aligned and identical
sequences grouped into mtDNA haplotypes. A subset of these
haplotypes has been reported previously [33]. The remainder were
classified based on their phylogenetic relatedness to subspecies
specific mtDNA reference sequences. Haplotypes and correspond-
ing GenBank accession numbers are listed in Table S1.
Phylogenetic analysis
Nucleotide sequences of SFVcpz gag, pol-RT and pol-IN
fragments were aligned using Se-Al (A. Rambaut, distributed by
the author at http://tree.bio.ed.ac.uk/software/seal/). Several
previously characterized SFVcpz strains were included as
reference sequences (GenBank accession numbers: SVFpvrc679,
AY195683 and AY195708; SFVprvc1138, AY195682;
SFVpvlcpz2, AY195686; SFVpvlcpz4, AY195687; CpzCam32,
AY639133; CpzCam19, AY639141; CpzCam21, AY639122;
SFVpsc925, AY195676 and AY195702; HFV, NC001795;
SFVptr1040, AY195673 and AY195699; SFVptr1436,
AY195700; SFVptrb1, AY195681 and AY195707; SFVcase6,
AY195712; SFVpsc5126, AY195701 and AY195675;
SFVpvra101, AY195678; SFVpvra055, AY195677; SFVpts-No,
AJ627552; SFVpts-Ni, AJ627553; SFVcase14, AY195719;
SFVcase13, AY195718; SFVpvra182, AY195706; SVFcase10,
AY195716; SFVcase8, AY195714; SFVpvra136, AY195705;
SFVcase9, AY195715; SFVcase12, AY195717; SFVcase7,
AY195713; SFVpvrc941, AY195685 and AY195709; SFVcpz,
NC001364; CpzCam44, AY639136; CpzCam30, AY639128;
CpzCam15, AY639138; CpzCam35, AY639130; PanGabNto,
AY639123; PanGabNte, AY639124; PanGabBel, AY639126;
Ppan1935, AJ627551; SFV-6, X83296; SFV-7, X83297). Very
few insertions or deletions were required to align the data, and the
resulting gaps were treated as unknown characters. All the
alignments are available from the authors upon request.
We initially used the Bayesian Markov chain Monte Carlo
(BMCMC) method implemented in MrBayes v3.1 [75] to infer
phylogenies for the mtDNA and SFV data. However, for some
data sets, most notably the pol-IN alignment, we observed that the
MCMC samples were dominated by trees that exhibited clearly
spurious branching patterns, with long branches leading to
distantly-related clades often breaking up the monophyly of
closely related groups of sequences (not shown). We therefore
employed the ‘relaxed molecular clock’ BMCMC method
implemented in BEAST [76], so-called because it relaxes the
assumption of a constant rate of evolution across the tree, allowing
different lineages to evolve at different rates. Although our interest
was not in estimating divergence dates, Drummond and colleagues
found that using a model that falls between the extremes of
assuming either a strict molecular clock or no molecular clock
appeared to improve both the accuracy and precision of topology
inference across a wide range of taxa [77]. Our results provide
further support for this conclusion, since the artifacts described
above for the MrBayes analyses were not observed in the BEAST
results.
All the BEAST runs were performed under an uncorrelated
lognormal relaxed molecular clock model with a constant
population size coalescent tree prior, using a general time-
reversible nucleotide substitution model with heterogeneity among
sites modeled with a gamma distribution. For each mtDNA and
SFVcpz data set, simultaneous sampling times were assumed since
the small intervals between sampling dates are expected to be
negligible given the long time span of evolution represented not
only by the mtDNA but also the SFV data sets [13].
For each analysis, two independent runs of 5 to 20 million steps
were performed. Examination of the MCMC samples with Tracer
v1.4 (A. Rambaut & A. J. Drummond, http://beast.bio.ed.ac.uk)
indicated convergence and adequate mixing of the Markov chains,
with estimated sample sizes in the 100s or 1000s. After inspection
with Tracer, we discarded an appropriate number of steps from
each run as burn-in, and combined the resulting MCMC tree
samples for subsequent estimation of posteriors. We summarized
the MCMC samples using the maximum clade credibility (MCC)
tree (including branch lengths) found using TreeAnnotator v1.4.7
[76], with posterior probabilities indicated (as percentages) for
nodes with P.0.90. All trees were saved with branch lengths
measured in substitutions per site rather than time.
Recombination and co-infection analyses
In order to investigate the possibility of recombination in
SFVcpz, and to map any putative recombination breakpoints, we
conducted a recombination detection analysis using GENECONV
[78]. GENECONV performs a series of comparisons between all
pairs of sequences in an alignment and asks whether certain
SFVcpz in Wild Chimpanzees
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www.math.wustl.edu/ ˜sawyer/geneconv/). For example, if two
sequences are nearly identical over one stretch of sequence, but
are highly divergent across the remainder, the similar fragment
might be detected by GENECONV as a putative mosaic region.
If, after statistically correcting for multiple comparisons, that
fragment still appears to be unexpectedly similar, it will be flagged
as a globally significant fragment by GENECONV. A simple
follow-up analysis with phylogenetic trees inferred from the
different regions detected by GENECONV can then confirm
whether certain sequences contain regions with conflicting
evolutionary histories (i.e. supporting significantly discordant
topologies).
GENECONV results on a concatenated alignment of strains for
which gag, pol-IN, and pol-RT sequences were available indicated
several globally significant fragments; however, because many of
the inferred breakpoints were at the gag-pol concatenation junction,
we investigated the possibility that the putative ‘‘recombinants’’
detected with these data set actually represented co-infected
samples in which different variants had been amplified for the
distinct regions comprising the concatenated data set. Because this
appeared to be the case, we restricted subsequent recombination
analyses to individually amplified gene regions.
Nucleotide sequence accession numbers
All newly obtained SFVcpz and mtDNA D-loop sequences have
been submitted to GenBank, and accession numbers are listed in
Tables S1 and S2, respectively.
Supporting Information
Figure S1 Subspecies origin of chimpanzee fecal samples.
Mitochondrial DNA sequences (498 bp D loop fragment) from
SFVcpz positive chimpanzee fecal specimens were grouped into
unique haplotypes (Table S1) and then compared to subspecies
specific reference sequences by phylogenetic analysis. Sequences
were analyzed using the Bayesian Markov chain Monte Carlo
(BMCMC) method implemented in BEAST. The maximum clade
credibility (MCC) topology is shown, with posterior probabilities
(expressed as percentages) indicated on nodes depicted either as
asterisks (100%) or filled circles (90%–99%). Haplotypes are color
coded according to their subspecies origin (a box denotes a P. t.
troglodytes haplotype identified in the range of P. t. vellerosus). The
scale bar represents 0.002 substitutions per site.
Found at: doi:10.1371/journal.ppat.1000097.s001 (0.86 MB EPS)
Table S1 Mitochondrial DNA analysis of primate fecal samples.
Found at: doi:10.1371/journal.ppat.1000097.s002 (0.29 MB
DOC)
Table S2 GenBank accession numbers of newly obtained SFV
sequences.
Found at: doi:10.1371/journal.ppat.1000097.s003 (2.50 MB
DOC)
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